Twenty-four–month event-free survival (EFS24) may predict for overall survival (OS) among patients with peripheral T cell lymphoma (PTCL), according to research published in the Journal of Clinical Oncology.1

PTCLs, which in the Western world consist primarily of anaplastic large-cell lymphoma, angioimmunoblastic T cell lymphoma, and PTCL not otherwise specified, are characterized by aggressive disease and poor response to chemotherapy. Previous study suggests that EFS is a prognostically relevant variable among patients with other lymphomas; for this study, researchers evaluated whether EFS24 predicts for overall survival in PTCL.

Of 775 patients included from 3 cohorts, only 36% reached EFS24. Among the 64% of patients who progressed within 24 months, the median OS was 4.9 months. The median among those who reached EFS24, in contrast, was not reached, with an expected 5-year OS rate of 78%.

After reaching EFS24, the 5-year relapse risk was 23%, with a median OS of 10.3 months post-relapse.

Patients 60 years and younger tended to have a longer OS after reaching EFS24; patients with ALK-negative disease were more likely reach EFS24, though they had a shorter OS thereafter.

Related Articles

The authors concluded that “more than one third of patients with PTCL remain in remission 2 years from diagnosis after initial chemotherapy and have encouraging OS rates, although survival remains significantly worse than the matched general population and risk of subsequent progression persists.”

Reference

  1. Maurer MJ, Ellin F, Srour L, et al. International assessment of event-free survival at 24 months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol. 2017 Oct 26. doi: 10.1200/JCO.2017.73.8195 [Epub ahead of print]